magazine recently "The New England Journal of Medicine (vol.356: 1915) has published clinical study showing the efficacy of a quadrivalent vaccine against strains of virus human papillomavirus that cause 70% of diagnosed cases of cervical cancer . About of 493,000 new cases of cancer are diagnosed each year in women worldwide, accounting for more than 80% to developing countries. In most cases the virus is transmitted sexually.
The study presented has lasted three years and has studied 27,000 women in 33 countries. The vaccine proved effective in preventing cervical lesions characterized as grade 2 and grade 3 and adenocarcinoma of in situ. The vaccine was more effective in women whose age had not had any contact with the virus, showing that a vaccination, as was alleged, would more effective if applied before any sexual contact, including school vaccination campaigns. There is however a drawback, the price of the three planned doses of the vaccine is $ 360, so these vaccination programs would be difficult to carry out in developing countries without the assistance of the Organization Health, the World Bank and other international agencies and foundations. It should be noted that vaccination does not alter the course of any pre-existing infections and in any case protect against viral strains with which contact has not existed before vaccination. It is important to note about this disease regularly monitor the effectiveness of gynecologic women, particularly between 25 and 45 years, cytology and even the rapid analysis of viral DNA can significantly reduce the risk of this cancer. The actual period of vaccine protection is unknown at this time is known to be at least 5 years follow-up will be needed more range time to learn this and other medical aspects. In any case, has taken an important step in the fight against this disease, it is predicted that a five-year delay in implementation of preventive vaccination policies in developing countries could mean the death of about two million women
